Cargando…

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study

BACKGROUND: Denosumab is a major treatment option for patients with postmenopausal osteoporosis; however, the evidence for its use is lacking. Therefore, in this 24-month retrospective study, we aimed to evaluate the effects of switching from minodronate (MIN) to denosumab in these patients. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Masaki, Sawada, Kenjiro, Yoshimura, Akihiko, Yamamoto, Misa, Shimizu, Aasa, Shimura, Kotaro, Komura, Naoko, Miyamoto, Mayuko, Ishida, Kyoso, Kimura, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057589/ https://www.ncbi.nlm.nih.gov/pubmed/32138724 http://dx.doi.org/10.1186/s12905-020-00913-x

Ejemplares similares

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells
por: Miyamoto, Mayuko, et al.
Publicado: (2020)

Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression
por: Nakamura, Koji, et al.
Publicado: (2019)

Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types
por: Kobayashi, Masaki, et al.
Publicado: (2018)

Three years of treatment with minodronate in patients with postmenopausal osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2011)

Minodronate for the treatment of osteoporosis
por: Ohishi, Tsuyoshi, et al.
Publicado: (2018)

Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target
por: Nakamura, Koji, et al.
Publicado: (2019)

Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells
por: Yoshimura, Akihiko, et al.
Publicado: (2018)

The effects of minodronate and activated vitamin D on bone mineral density and muscle mass in postmenopausal women with osteoporosis
por: Fujimoto, Kazuki, et al.
Publicado: (2018)

The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis
por: Hasegawa, Eriko, et al.
Publicado: (2018)

A review of minodronic acid hydrate for the treatment of osteoporosis
por: Tanishima, Shinji, et al.
Publicado: (2013)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
por: Okazaki, R., et al.
Publicado: (2011)

Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis
por: Liu, Qingshan, et al.
Publicado: (2020)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
por: Słopień, Radosław, et al.
Publicado: (2017)

Influence on the bone mineral density and bone metabolism marker after the interruption and reinitiation of monthly minodronate therapy in postmenopausal women with osteoporosis
por: Okimoto, Nobukazu, et al.
Publicado: (2018)

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
por: Cairoli, Elisa, et al.
Publicado: (2015)

Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea
por: Kang, Jung-Yoon, et al.
Publicado: (2022)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Pathophysiological Role and Potential Therapeutic Exploitation of Exosomes in Ovarian Cancer
por: Shimizu, Aasa, et al.
Publicado: (2020)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
por: Johnson, Ben, et al.
Publicado: (2021)

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review
por: Nargesi, Shahin, et al.
Publicado: (2022)

Identification of Malignant Cell Populations Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer Using Single-Cell RNA Sequencing
por: Sumitani, Naoki, et al.
Publicado: (2022)

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study
por: Matsumoto, T., et al.
Publicado: (2008)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Utility of monthly minodronate for osteoporosis after gastrectomy: Prospective multicenter randomized controlled trials
por: Hirota, Masashi, et al.
Publicado: (2021)

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
por: Watts, N. B., et al.
Publicado: (2011)

Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab
por: Scheiner, S, et al.
Publicado: (2014)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4omkt2aejvbodhbh9rtobf76hm